Condition: Ischemic Stroke · Sponsor: Pharmasoft
The primary objective of this study is to further define the mechanisms of action of Mexidol® (solution for intravenous and intramuscular injection, 50 mg/ml) and Mexidol® FORTE 250 (film-coated tablets, 250 mg) in the hyperacute and acute periods of ischemic stroke, and to evaluate their impact on clinical and neuroimaging outcomes of the disease.
This description comes directly from the study's public registry record.
Yuriy E. Meshcherskiy, Medical Director, LLC "RPC "PHARMASOFT", Medical Director · 007 (495) 626-47-55 · pharmasoft@pharmasoft.ru
Always discuss trial participation with your own doctor first.
| First City Clinical Hospital named after E.E. Volosevich | Arkhangelsk, Russia | Recruiting |
| Ivanovo Regional Clinical Hospital | Ivanovo, Russia | Recruiting |
| Regional Clinical Hospital | Ryazan, Russia | Recruiting |
| Hospital for War Veterans | Saint Petersburg, Russia | Recruiting |
| City Hospital № 40 of Kurortny District | Saint Petersburg, Russia | Recruiting |
| Smolensk Regional Clinical Hospital | Smolensk, Russia | Recruiting |
| Regional Clinical Hospital | Tver', Russia | Recruiting |
| Regional Clinical Hospital | Yaroslavl, Russia | Recruiting |
| Zhukovskiy Regional Clinical Hospital, | Zhukovskiy, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07575984